Novel frontiers of dedicated molecular imaging in breast cancer diagnosis

Angela Collarino, Valentina Fuoco, Lenka M.Pereira Arias-Bouda, Alejandro M. Sánchez, Lioe Fee de Geus-Oei, Riccardo Masetti, Renato A.Valdés Olmos

Research output: Contribution to journalReview article

Abstract

Breast cancer (BC) is the most common cancer in women worldwide. In the last years, the contribution of nuclear medicine has grown based on the use of dedicated molecular breast devices for diagnosis and biopsy. Recent technical improvements have been achieved in order to increase the detection of smaller breast lesions using lower doses of radiotracers as well as to facilitate accurate biopsy sampling. Furthermore, new prototypes have been developed combining anatomic and functional imaging. Although the gamma-emitting 99mTc-sestamibi (99mTc-MIBI) and the positron-emitting 18F-fluorodeoxyglucose (18F-FDG) are the most widely used radiotracers, several new tracers have been investigated to target more specific biologic features of BC like proliferation, angiogenesis and tumour receptor status. Dedicated molecular breast devices have been introduced as an adjunct imaging tool to mammography (MG) and ultrasound (US) in the clinical work-up for BC. Additionally, due to the increased interest in molecular tumour subtype analysis and ribonucleic acid (RNA)-based gene expression profiling tests in the routine clinical practice, a possible new clinical application of dedicated breast imaging concerns locally advanced BC, principally in order to visualise intra-tumour metabolic heterogeneity enabling selection of areas with highest tracer uptake (vital tissue) for core needle biopsy. Hence, it will be possible to more adequately tailor the individual treatment, also enabling therapy response monitoring. This review evaluates the current and future perspectives as well as the shortcomings of breast imaging using dedicated nuclear medicine devices.

Original languageEnglish
Pages (from-to)S295-S306
JournalTranslational Cancer Research
Volume7
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Molecular Imaging
Breast
Breast Neoplasms
Nuclear Medicine
Equipment and Supplies
Neoplasms
Mammary Ultrasonography
Large-Core Needle Biopsy
Technetium Tc 99m Sestamibi
Biopsy
Fluorodeoxyglucose F18
Gene Expression Profiling
RNA
Electrons
Therapeutics

Keywords

  • Breast cancer (BC)
  • Breast dedicated systems
  • Radiotracer-guided biopsy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Collarino, A., Fuoco, V., Arias-Bouda, L. M. P., Sánchez, A. M., de Geus-Oei, L. F., Masetti, R., & Olmos, R. A. V. (2018). Novel frontiers of dedicated molecular imaging in breast cancer diagnosis. Translational Cancer Research, 7, S295-S306. https://doi.org/10.21037/tcr.2017.10.28

Novel frontiers of dedicated molecular imaging in breast cancer diagnosis. / Collarino, Angela; Fuoco, Valentina; Arias-Bouda, Lenka M.Pereira; Sánchez, Alejandro M.; de Geus-Oei, Lioe Fee; Masetti, Riccardo; Olmos, Renato A.Valdés.

In: Translational Cancer Research, Vol. 7, 01.04.2018, p. S295-S306.

Research output: Contribution to journalReview article

Collarino, A, Fuoco, V, Arias-Bouda, LMP, Sánchez, AM, de Geus-Oei, LF, Masetti, R & Olmos, RAV 2018, 'Novel frontiers of dedicated molecular imaging in breast cancer diagnosis', Translational Cancer Research, vol. 7, pp. S295-S306. https://doi.org/10.21037/tcr.2017.10.28
Collarino A, Fuoco V, Arias-Bouda LMP, Sánchez AM, de Geus-Oei LF, Masetti R et al. Novel frontiers of dedicated molecular imaging in breast cancer diagnosis. Translational Cancer Research. 2018 Apr 1;7:S295-S306. https://doi.org/10.21037/tcr.2017.10.28
Collarino, Angela ; Fuoco, Valentina ; Arias-Bouda, Lenka M.Pereira ; Sánchez, Alejandro M. ; de Geus-Oei, Lioe Fee ; Masetti, Riccardo ; Olmos, Renato A.Valdés. / Novel frontiers of dedicated molecular imaging in breast cancer diagnosis. In: Translational Cancer Research. 2018 ; Vol. 7. pp. S295-S306.
@article{4ae64474b975420b803c116c3e18f241,
title = "Novel frontiers of dedicated molecular imaging in breast cancer diagnosis",
abstract = "Breast cancer (BC) is the most common cancer in women worldwide. In the last years, the contribution of nuclear medicine has grown based on the use of dedicated molecular breast devices for diagnosis and biopsy. Recent technical improvements have been achieved in order to increase the detection of smaller breast lesions using lower doses of radiotracers as well as to facilitate accurate biopsy sampling. Furthermore, new prototypes have been developed combining anatomic and functional imaging. Although the gamma-emitting 99mTc-sestamibi (99mTc-MIBI) and the positron-emitting 18F-fluorodeoxyglucose (18F-FDG) are the most widely used radiotracers, several new tracers have been investigated to target more specific biologic features of BC like proliferation, angiogenesis and tumour receptor status. Dedicated molecular breast devices have been introduced as an adjunct imaging tool to mammography (MG) and ultrasound (US) in the clinical work-up for BC. Additionally, due to the increased interest in molecular tumour subtype analysis and ribonucleic acid (RNA)-based gene expression profiling tests in the routine clinical practice, a possible new clinical application of dedicated breast imaging concerns locally advanced BC, principally in order to visualise intra-tumour metabolic heterogeneity enabling selection of areas with highest tracer uptake (vital tissue) for core needle biopsy. Hence, it will be possible to more adequately tailor the individual treatment, also enabling therapy response monitoring. This review evaluates the current and future perspectives as well as the shortcomings of breast imaging using dedicated nuclear medicine devices.",
keywords = "Breast cancer (BC), Breast dedicated systems, Radiotracer-guided biopsy",
author = "Angela Collarino and Valentina Fuoco and Arias-Bouda, {Lenka M.Pereira} and S{\'a}nchez, {Alejandro M.} and {de Geus-Oei}, {Lioe Fee} and Riccardo Masetti and Olmos, {Renato A.Vald{\'e}s}",
year = "2018",
month = "4",
day = "1",
doi = "10.21037/tcr.2017.10.28",
language = "English",
volume = "7",
pages = "S295--S306",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Novel frontiers of dedicated molecular imaging in breast cancer diagnosis

AU - Collarino, Angela

AU - Fuoco, Valentina

AU - Arias-Bouda, Lenka M.Pereira

AU - Sánchez, Alejandro M.

AU - de Geus-Oei, Lioe Fee

AU - Masetti, Riccardo

AU - Olmos, Renato A.Valdés

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Breast cancer (BC) is the most common cancer in women worldwide. In the last years, the contribution of nuclear medicine has grown based on the use of dedicated molecular breast devices for diagnosis and biopsy. Recent technical improvements have been achieved in order to increase the detection of smaller breast lesions using lower doses of radiotracers as well as to facilitate accurate biopsy sampling. Furthermore, new prototypes have been developed combining anatomic and functional imaging. Although the gamma-emitting 99mTc-sestamibi (99mTc-MIBI) and the positron-emitting 18F-fluorodeoxyglucose (18F-FDG) are the most widely used radiotracers, several new tracers have been investigated to target more specific biologic features of BC like proliferation, angiogenesis and tumour receptor status. Dedicated molecular breast devices have been introduced as an adjunct imaging tool to mammography (MG) and ultrasound (US) in the clinical work-up for BC. Additionally, due to the increased interest in molecular tumour subtype analysis and ribonucleic acid (RNA)-based gene expression profiling tests in the routine clinical practice, a possible new clinical application of dedicated breast imaging concerns locally advanced BC, principally in order to visualise intra-tumour metabolic heterogeneity enabling selection of areas with highest tracer uptake (vital tissue) for core needle biopsy. Hence, it will be possible to more adequately tailor the individual treatment, also enabling therapy response monitoring. This review evaluates the current and future perspectives as well as the shortcomings of breast imaging using dedicated nuclear medicine devices.

AB - Breast cancer (BC) is the most common cancer in women worldwide. In the last years, the contribution of nuclear medicine has grown based on the use of dedicated molecular breast devices for diagnosis and biopsy. Recent technical improvements have been achieved in order to increase the detection of smaller breast lesions using lower doses of radiotracers as well as to facilitate accurate biopsy sampling. Furthermore, new prototypes have been developed combining anatomic and functional imaging. Although the gamma-emitting 99mTc-sestamibi (99mTc-MIBI) and the positron-emitting 18F-fluorodeoxyglucose (18F-FDG) are the most widely used radiotracers, several new tracers have been investigated to target more specific biologic features of BC like proliferation, angiogenesis and tumour receptor status. Dedicated molecular breast devices have been introduced as an adjunct imaging tool to mammography (MG) and ultrasound (US) in the clinical work-up for BC. Additionally, due to the increased interest in molecular tumour subtype analysis and ribonucleic acid (RNA)-based gene expression profiling tests in the routine clinical practice, a possible new clinical application of dedicated breast imaging concerns locally advanced BC, principally in order to visualise intra-tumour metabolic heterogeneity enabling selection of areas with highest tracer uptake (vital tissue) for core needle biopsy. Hence, it will be possible to more adequately tailor the individual treatment, also enabling therapy response monitoring. This review evaluates the current and future perspectives as well as the shortcomings of breast imaging using dedicated nuclear medicine devices.

KW - Breast cancer (BC)

KW - Breast dedicated systems

KW - Radiotracer-guided biopsy

UR - http://www.scopus.com/inward/record.url?scp=85045924576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045924576&partnerID=8YFLogxK

U2 - 10.21037/tcr.2017.10.28

DO - 10.21037/tcr.2017.10.28

M3 - Review article

AN - SCOPUS:85045924576

VL - 7

SP - S295-S306

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

ER -